Humacyte Inc [NASDAQ: HUMA] closed the trading session at $1.79 on 2025-09-18. The day’s price range saw the stock hit a low of $1.57, while the highest price level was $1.88.
The stocks have a year to date performance of -66.10 percent and weekly performance of 19.33 percent. The stock has been moved at -45.92 percent over the last six months. The stock has performed 12.23 percent around the most recent 30 days and changed -24.15 percent over the most recent 3-months.
If compared to the average trading volume of 4.22M shares, HUMA reached to a volume of 9149899 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Humacyte Inc [HUMA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HUMA shares is $8.43 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HUMA stock is a recommendation set at 1.43. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Barclays have made an estimate for Humacyte Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on August 27, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on May 14, 2025, representing the official price target for Humacyte Inc stock. Previously, the target price had yet another raise from $12 to $15, while H.C. Wainwright kept a Buy rating on HUMA stock.
The Price to Book ratio for the last quarter was 69.06, with the Price to Cash per share for the same quarter was set at 0.24.
HUMA stock trade performance evaluation
Humacyte Inc [HUMA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 19.33. With this latest performance, HUMA shares gained by 12.23% in over the last four-week period, additionally sinking by -45.92% over the last 6 months – not to mention a drop of -64.55% in the past year of trading.
Humacyte Inc [HUMA]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Humacyte Inc [HUMA] shares currently have an operating margin of -13598.04% and a Gross Margin at -837.90%. Humacyte Inc’s Net Margin is presently recorded at -7461.49%.
Humacyte Inc (HUMA) Capital Structure & Debt Analysis
According to recent financial data for Humacyte Inc. ( HUMA), the Return on Equity (ROE) stands at -257.38%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -44.06%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Humacyte Inc’s Return on Invested Capital (ROIC) is -73.98%, showcasing its effectiveness in deploying capital for earnings.
Humacyte Inc (HUMA) Efficiency & Liquidity Metrics
Based on Humacyte Inc’s (HUMA) latest financial statements, the Debt-to-Equity Ratio is 20.66%, indicating its reliance on debt financing relative to shareholder equity.
Humacyte Inc (HUMA) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Humacyte Inc. (HUMA) effectively leverages its workforce, generating an average of -$277409.09 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.45% and a Quick Ratio of 1.93%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Humacyte Inc [HUMA] stock
With the latest financial reports released by the company, Humacyte Inc posted -0.26/share EPS, while the average EPS was predicted by analysts to be reported at -0.25/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.01. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HUMA.
Humacyte Inc [HUMA]: Institutional Ownership
There are presently around $36.38%, or 45.33%% of HUMA stock, in the hands of institutional investors. The top three institutional holders of HUMA stocks are: BLACKROCK INC. with ownership of 7.14 million shares, which is approximately 5.9912%. VANGUARD GROUP INC, holding 4.73 million shares of the stock with an approximate value of $$22.7 million in HUMA stocks shares; and VANGUARD GROUP INC, currently with $$13.77 million in HUMA stock with ownership which is approximately 2.4071%.
